# Treatment with non-automated insulin pumps or multiple daily injections during pregnancy and post-delivery in women with type 1 diabetes: A secondary analysis of the CopenFast trial

**Authors:** Katrine Christiansen, Sidse K. Nørgaard, Kirsten Nørgaard, Tine D. Clausen, Peter Damm, Elisabeth R. Mathiesen, Lene Ringholm

PMC · DOI: 10.1007/s00592-025-02560-w · Acta Diabetologica · 2025-08-04

## TL;DR

This study compared insulin pump and injection use during pregnancy in women with type 1 diabetes, finding no better outcomes with pumps despite similar blood sugar control.

## Contribution

The study provides new evidence on the lack of improved pregnancy outcomes with non-automated insulin pumps versus injections in T1D patients.

## Key findings

- Insulin pump users had higher rates of preterm delivery and C-sections compared to MDI users.
- Glycemic control was similar between insulin pump and MDI users during pregnancy.
- Post-delivery maternal and infant outcomes were similar between the two groups.

## Abstract

To evaluate pregnancy and post-delivery outcomes with non-automated insulin pumps or multiple daily injections (MDI) in women with type 1 diabetes (T1D).

A preplanned secondary analysis of the CopenFast trial including women with T1D using continuous glucose monitoring (CGM), primarily intermittently scanned CGM, routinely. Pregnancy and post-delivery outcomes were compared between insulin pump users and MDI users. Insulin pump settings during pregnancy and post-delivery were compared to pre-pregnancy.

Of 141 women, 39 used non-automated insulin pumps and 102 used MDI. Median diabetes duration was 17 (IQR 12–20) vs. 14 (8–21) years (P = 0.12). HbA1c was 48 (44–53) mmol/mol vs. 47 (42–53) at 9 weeks (P = 0.65) and 43 (40–46) vs. 43 (39–46) at 35 weeks (P = 0.53). Mean sensor glucose decreased from ~ 7.0 mmol/l at 9 weeks to 6.3 mmol/l at 33 weeks in both groups. Preterm delivery (< 37 weeks) was more common with insulin pumps (25.9% vs. 16.7%, P = 0.01), as was caesarean section (59% vs. 40%, P = 0.04), which was independent of diabetes duration, age and microvascular complications. At 1 and 3 months post-delivery, maternal and infant outcomes, including breastfeeding, were similar between groups. In insulin pump users, basal insulin rates were ~ 37% higher, and carbohydrate-to-insulin ratios ~ 61% lower at 33 weeks while basal insulin rates were ~ 20% lower, and carbohydrate-to-insulin ratios were similar 3 months post-delivery, compared to pre-pregnancy.

Despite routine use of CGM and similar glycaemic control, non-automated insulin pump users did not achieve improved pregnancy outcomes compared to MDI users.

## Linked entities

- **Diseases:** type 1 diabetes (MONDO:0005147)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** T1D (MESH:D003922), diabetes (MESH:D003920)
- **Chemicals:** glucose (MESH:D005947), carbohydrate (MESH:D002241)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12847073/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12847073/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12847073/full.md

---
Source: https://tomesphere.com/paper/PMC12847073